• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by ImmunoPrecise Antibodies Ltd.

    7/7/23 3:22:18 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPA alert in real time by email
    SC 13D 1 immunoprecise13disjuly7.txt Schedule 13D ------------------------------------------- OMB APPROVAL ------------------------------------------- OMB Number: Expires: Estimated average burden hours per form................... ------------------------------------------- UNITED STAES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. N/A)* ImmunoPrecise Antibodies Ltd. -------------------------------------------------------------------------------- (Name of Issuer) Common -------------------------------------------------------------------------------- (Title of Class of Securities) 45257F200 -------------------------------------------------------------------------------- (CUSIP Number) Christian C. Park Ingalls & Snyder, LLC 1325 Avenue of the Americas New York, NY 10019 (212) 269-7894 -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 29, 2023 -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]. *The remainder of this cover page shall be filed out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) CUSIP No. 45257F200 13D -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Ingalls & Snyder, LLC -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ X] -------------------------------------------------------------------------------- 3 SEC USE ONLY -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* OO -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New York -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH 0 REPORTING -------------------------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH 0 -------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 1,053,186 -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,053,186 -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.22% -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IA -------------------------------------------------------------------------------- The Shares reported herein are not limited to, but include those of the personal accounts of William McHale, an advisor representative of the Reporting Person. All of the individuals are advisory clients of the Reporting Person. The following Items are amended and restated in their entirety: Item 1. Security and Issuer ImmunoPrecise Antibodies Ltd. Common Stock (the "Shares") 3204 4464 Markham Street Victoria, BC V8Z 7X8 Item 2. Identity and Background (a)Ingalls & Snyder, LLC The Reporting Person is a limited liability company organized under the laws of the State of New York. (b)Business address and principal office for the Reporting Person: (c)Present principal occupation or employment and the name, principal business and address where employment occurs. (d) During the last five years,the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, and is not subject to a judgment, decree or final order enjoining future violations of,or prohibiting or mandating activities subject to, federalor state securities laws or finding any violation with respect to such laws. (f)Citizenship: Item 3. Source and Amount of Funds or Other Consideration. Personal funds of Reporting Persons' advisory clients. Item 4. Purpose of Transaction The Reporting Person along with other shareholders are collectively proposing a change to the members of the issuers board of directors. The views of the informal group will be expressed through written and oral communications, and may result in a call for a shareholder meeting on the issue. While the Reporting Person is along under the filing threshold requirement, it is electing to file this Schedule D as it is a part of a group of shareholders who share a common goal of effecting a change to the board members. There are no formal written agreements with other shareholders to act as a group. Item 5. Interest in Securities of the Issuer (a) The Reporting Person is the beneficial owner of 1,053,186 shares which is equivalent to 4.22% of the outstanding shares of the issuer based on the total number of outstanding shares reported by the issuer on its most recent Form 10-Q. The Reporting Person has the sole power to dispose of or direct the disposition of 0 shares, shared power to dispose of or direct the disposition of 1,053,186 shares, and shared voting power of 1,053,186 shares. (d) Not applicable. (e) Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. None Item 7. Material to be Filed as Exhibits. None Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: July 7, 2023 /s/ Christian C. Park Christian C. Park
    Get the next $IPA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IPA

    DatePrice TargetRatingAnalyst
    12/2/2022$9.00Buy
    H.C. Wainwright
    10/25/2021$12.00Buy
    Benchmark
    10/25/2021$12.00Buy
    The Benchmark Company
    More analyst ratings

    $IPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

      Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential ImmunoPrecise (NASDAQ:IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. "This is a major step forward," said Dr. Jennifer Bath,

      6/24/25 7:02:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

      Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. The r

      6/12/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

      LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. This discovery mark

      6/5/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

      H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

      12/2/22 8:15:24 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

      Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:31:59 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

      The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:28:32 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    SEC Filings

    See more
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/3/25 9:40:55 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      6/24/25 8:00:38 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      6/12/25 8:25:06 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Leadership Updates

    Live Leadership Updates

    See more
    • ImmunoPrecise Antibodies Announces Key Leadership Changes

      ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224016053/en/Kamil Isaev (Photo: Business Wire) Kamil Isaev Joins IPA's Board of Directors IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its

      2/24/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA Announces Resignation of Chief Financial Officer

      ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. "Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors." IPA has initiated a CFO succession process and will p

      12/31/24 7:56:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

      University of Washington's Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of computational tools and AI in advancing our understanding of protein structures—principles that are central to IPA's

      10/10/24 8:10:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      2/27/24 10:33:04 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoPrecise Antibodies Ltd. (Amendment)

      SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:53:08 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:33:21 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Financials

    Live finance-specific insights

    See more
    • ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

      Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug disc

      3/28/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data

      3/11/25 10:17:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and

      3/5/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care